Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study-Reference-Cited by-同舟云学术

Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study

Published:2024-08 Issue:8 Volume:11 Page:e567-e579
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Hu Yu,Liu Xiaofan,Zhou Hu,Wang Shujie,Huang Ruibin,Wang Yi,Du Xin,Sun Jing,Zhou Zeping,Yan Zhenyu,Chen Wenming,Wang Wei,Liu Qingchi,Zeng Qingshu,Gong Yuping,Yin Jie,Shen Xuliang,Ye Baodong,Chen Yun,Xu Yajing,Sun Huiping,Cheng Yunfeng,Liu Zhuogang,Wang Chunling,Yuan Guolin,Zhang Xiaohui,Li Xin,Cheng Peng,Guo Xinhong,Jiang Zhongxing,Yang Feng'e,Yang Linhua,Luo Chengwei,Xiao Taiwu,Fu Sisi,Yin Hongyan,Guo Xiaojun,Xu Qian,Fan Songhua,Shi Michael M,Su Weiguo,Mei Heng,Yang Renchi

Publisher

Elsevier BV

Reference29 articles.

1. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group;Rodeghiero;Blood,2009

2. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management;Stasi;Thromb Haemost,2008

3. American Society of Hematology 2019 guidelines for immune thrombocytopenia;Neunert;Blood Adv,2019

4. Clinical updates in adult immune thrombocytopenia;Lambert;Blood,2017

5. Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP);Zufferey;J Clin Med,2017

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sovleplenib in immune thrombocytopenia;The Lancet Haematology;2024-08

2. Clinical trial landscape for immune thrombocytopenia: Progress and the long road ahead;European Journal of Internal Medicine;2024-08